Reported 19 days ago
Novo Nordisk has announced mixed results for its third quarter, narrowing its full-year sales growth guidance while achieving a remarkable 79% year-over-year increase in sales for its weight-loss drug Wegovy. The company's CFO highlighted significant growth in both US and international sales of GLP-1 products.
Source: YAHOO